Biogen expects pipeline boost
Cambridge, MA, US-based Biogen expects to havedouble the number of drugs in its clinical pipeline over the course of 2001, says its president and chief executive, James Mullen. Speaking in San Francisco, Mullen highlighted three drugs scheduled for clinical trials this year: an adenosine A1 antagonists for congestiove heart failure; a soluble lymphotoxin beta receptor for autoimmune diseases, and an interferon beta gene therapy for glioma. The company also expects to have data from Phase III clinical trials of its chronic plaque psoriasis treatment, Amevive, by the middle of the year.